A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Non-transfusion-dependent ThalassemiaLow Risk Myelodysplastic SyndromeVery-Low Risk Myelodysplastic Syndrome
Interventions
DRUG

SLN124

SLN124 for subcutaneous (s.c.) injection

DRUG

Placebo

Sodium chloride for s.c. injection

Trial Locations (20)

Unknown

Universitaetsklinikum Duesseldorf, Düsseldorf

Universitat Leipzig, Leipzig

Rambam Health Care Campus, Haifa

Sheba Medical Center, Ramat Gan

Bar-Ilan University - Faculty of Medicine, Safed

Tel Aviv Sourasky Medical Center, Tel Aviv

AUSL della Romagna - Ospedale di Ravenna, Ravenna

Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia

Jordan University Hospital, Amman

King Hussein Cancer Center, Amman

Irbid Speciality Hospital, Irbid

Sarawak General Hospital, Kampung Sarawak

Hospital Ampang, Kampung Selangor

King Chulalongkorn Memorial Hospital, Bangkok

Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok

Mahidol University - Siriraj Hospital, Bangkok

Faculty of Medicine, Chiang Mai University, Chiang Mai

University Hospital of Wales, Cardiff

The Leeds Teaching Hospitals NHS Trust - Saint James's University Hospital, Leeds

Hammersmith Medicines Research Ltd (HMR), London

All Listed Sponsors
lead

Silence Therapeutics plc

INDUSTRY